The estimated Net Worth of Peter B. Silverman is at least $1.12 Million dollars as of 27 June 2024. Mr Silverman owns over 10,000 units of Merus N.V stock worth over $502,800 and over the last 5 years he sold MRUS stock worth over $0. In addition, he makes $614,879 as Exec. VP, Gen. Counsel, and Chief Intellectual Property Officer and Head of Utrecht & US Legal at Merus N.V.
Mr has made over 4 trades of the Merus N.V stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of MRUS stock worth $179,400 on 27 June 2024.
The largest trade he's ever made was exercising 62,000 units of Merus N.V stock on 17 June 2024 worth over $1,510,320. On average, Mr trades about 14,035 units every 76 days since 2020. As of 27 June 2024 he still owns at least 10,000 units of Merus N.V stock.
You can see the complete history of Mr Silverman stock trades at the bottom of the page.
Peter B. Silverman J.D. is the Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal at Merus N.V.
As the Exec. VP, Gen. Counsel, and Chief Intellectual Property Officer and Head of Utrecht & US Legal of Merus N.V, the total compensation of Mr D at Merus N.V is $614,879. There are 2 executives at Merus N.V getting paid more, with Hui Liu having the highest compensation of $1,382,530.
Mr D is 43, he's been the Exec. VP, Gen. Counsel, and Chief Intellectual Property Officer and Head of Utrecht & US Legal of Merus N.V since . There are 15 older and 1 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
Peter's mailing address filed with the SEC is C/O MERUS N.V., UPPSALALAAN 17, UTRECHT, P7, 3584 CT.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: